Piper Sandler analyst Joseph Catanzaro downgrades $ESSA Pharma (EPIX.US)$ to a hold rating, and adjusts the target price from $15 to $2.
According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of 10.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $ESSA Pharma (EPIX.US)$'s main analysts recently are as follows:
Following a prespecified futility analysis, it was revealed that Essa Pharma's masofaniten failed to achieve the desired efficacy profile in the Phase 2 enzalutamide combination study. The company will cease all development of this candidate. Further details are anticipated as the company embarks on a strategic review to explore alternatives that could enhance shareholder value.
The company has ceased all masofaniten programs following an interim analysis from its Phase 2 trial, which did not demonstrate any advantage of the combination therapy over the monotherapy in metastatic castration-resistant prostate cancer. The quick decision to halt these programs and concentrate on strategic alternatives is deemed judicious, despite the negative outcome. The lack of clarity regarding future direction and the absence of additional assets in various stages of development are contributing factors to the change in outlook.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
派杰投资分析师Joseph Catanzaro下调$ESSA Pharma (EPIX.US)$至持有评级，并将目标价从15美元下调至2美元。
根据TipRanks数据显示，该分析师近一年总胜率为44.8%，总平均回报率为10.3%。
此外，综合报道，$ESSA Pharma (EPIX.US)$近期主要分析师观点如下：
经过预先规定的徒劳分析，发现Essa Pharma的masofaniten在2期恩杂鲁胺联合研究中未能达到预期的疗效。该公司将停止对该候选人的所有开发。随着公司开始进行战略审查，以探索可以提高股东价值的替代方案，预计会有更多细节。
在对其2期试验进行中期分析后，该公司已停止所有masofaniten项目，该试验没有显示联合疗法在转移性去势抵抗性前列腺癌中与单一疗法相比有任何优势。尽管结果不利，但迅速决定停止这些计划并专注于战略选择被认为是明智的。未来方向不明确，各个发展阶段缺乏额外资产，是前景变化的促成因素。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
